Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot!
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
The Great Debate: To Treat or Not to Treat Pre RA
Dr. Janet Pope and Dr. Jonathan Kay discuss the Great Debate, which Dr. Pope participated in, at ACR22 Convergence in Philadelphia, PA.
Watch video →
COVID Highlights
Dr. Leonard Calabrese and Dr. Cassandra Calabrese share highlights on COVID data being presented at ACR22 Convergence. Abstract 0793: Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation Abstract L08: Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders
Watch video →
To Switch or Not: Biosimilars in Inflammatory Arthritis
Dr. Jonathan Kay reports on abstract 1112 at ACR22 Convergence.
Watch video →
Switch vs Cycle in PsA
Dr. Arthur Kavanaugh discusses abstract 1600 at ACR22 Convergence. Abstract 1600: The Impact of Second-Line Therapeutic on Disease Control After Discontinuation of First Line TNF Inhibitor in Patients with PsA: Analysis from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Watch video →
New Treatments for SLE?
Dr. Michelle Petri discusses abstract 1117 presented at ACR22 Convergence meeting in Philadelphia, PA. Abstract 1117: Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Watch video →
Best of PsA on Day 1
Dr. Rachel Tate discusses the best PSA data presented Saturday, November 12, 2002 at ACR22 Convergence. Abstract 0387: Sleep Quality in Patients with Psoriatic Arthritis and Its Relationship with Activity and Comorbidity Abstract 0377: Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RESPONDIA and REGISPONSER Studies
Watch video →
Urinary Biomarkers in Lupus
Dr. Jack Cush interviews Dr. Andrea Fava about Abstract 536 at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 0536: Change in Urinary Biomarkers at Three Months Predicts 1-year Treatment Response of Lupus Nephritis Better Than Proteinuria
Watch video →
A Novel Treatment Response Measurement Tool for Lupus
Dr. Kathryn Dao discusses abstract 2054 with Dr. Eric Morand at the ACR22 Convergence meeting. Abstract 2054: Towards a Novel Clinician-Reported Outcome Measure for SLE – Outcomes of an International Consensus Process.
Watch video →
Dr. Rachel Tate uptoTate
3 years 10 months ago
Korean KOBIO-AS registry: Infection incidence 26 events/1000 PY (URI > zoster most common) Risks: ischemic heart disease, ASDAS-ESR >3.5, complicated DM, abnormal chest x-ray, current bDMARDs. Male gender was protective. Abs 0372 #ACR22 @RheumNow https://t.co/i1JyFuriFz
Richard Conway RichardPAConway
3 years 10 months ago
Christ et al. 1 year follow up of GUSTO - tocilizumab monotherapy in GCA after 3 days only of steroid. Week 52 - 13/18 in relapse free remission. Week 104 12/18 in relapse free remission @rheumnow #ACR22 Abstr#0470 #ACRbest https://t.co/Pnvoeqb8rp https://t.co/dB6F25Krgg
Richard Conway RichardPAConway
3 years 10 months ago
Gomez et al. RA patient derived ACPAs both prevent and ameliorate collagen-antibody induced arthritis when given at early but not late stage in an animal model. Appears to be mediated through NETs @rheumnow #ACR22 Abstr#0045 https://t.co/HSD0oZBaha https://t.co/OqTv4XLXws
Richard Conway RichardPAConway
3 years 10 months ago
Bui et al. Screening for ANCA in ILD. Present in 9.8% . 65.4% of these had AAV. No difference in pulmonary outcomes. More steroids, immunosuppressives, hospitalisations. @rheumnow #ACR22 Abstr#0438 https://t.co/RGdnDWSpNF https://t.co/xYeCUoTqqy
Dr. Rachel Tate uptoTate
3 years 10 months ago
Endothelin-1, pro-inflammatory protein involved in multiple vascular and fibrosing abnormalities, may be a biomarker for differentiating between IPF and IIM-ILD or SSc-ILD. I'm always interested in potential biomarkers for clinic! Abs 0123 #ACR22 @RheumNow https://t.co/I69X4V0Zoa
Julian Segan JulianSegan
3 years 10 months ago
BIOBADASER cohort showing risk of incident cancer in rheumatic disease and previous malignancy was not difference between TNFi and other biologics/tsDMARDs. Need bigger numbers (esp with JAKi) to really reassure.
@RheumNow ABST0267 #ACR22 #ACRBest
https://t.co/0YutuCBOb8 https://t.co/btYrCA6UDh
Olga Petryna DrPetryna
3 years 10 months ago
#abst037 #acr22 @rheumnow REGISPONSER & RESPONDIA study of 231 pts w/late- vs early-onset PsA: late-onset> often male , ⬆️structural damage, ⬆️ FASFI, ⬆️ UE arthritis. Sacroiliitis& enthesitis ⬇️ frequent in late-onset. No effect on quality of life, dis activity & Rx choice https://t.co/IPRc1r2sxZ
Catherine Sims, MD DrCassySims
3 years 10 months ago
How do we decide which RA patients are best for #telehealth?
Abstract #1291, Ignite session
🖥@DavidLeverenz et. al created a predictive model to answer this question
🖥Patient age, diagnosis, medications, and RAPID3 score impacted the model
@RheumNow #ACR22 https://t.co/JztTbQ4zfZ
Richard Conway RichardPAConway
3 years 10 months ago
Leung et al @drceowen @drdavidliew persistence of fatigue, sleep and mood disorders in treated PMR patients in clinical remission. higher PSQI (lower quality sleep), higher BRAF (fatigue), higher HAD (depression, anxiety) @rheumnow #ACR22 Abstr#0204 https://t.co/zoeBNO6vVD https://t.co/TGC57kj6of
Today's plenary session features a novel proposal on how and which patients with Idiopathic Inflammatory Myopathy (IIM) should be screened for cancer. Abstract 0002 by Oldroyd et al, entitled "Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy" took on this thorny practice issue.
Patricia Harkins DrTrishHarkins
3 years 10 months ago
RTX vs CYCLO for CTD ILD
🌟RECITAL trial🌟
🫁Best ⬆️ in lung fn seen in IIM + MCTD assoc ILD for both agents
🫁SSc-ILD- lung function stabilisation only (no ⬆️)
👉 In SSc RTX improved skin thickness (mRss 24wks)
⬇️ a/e RTX
#ACR22 @RheumNow
Abst#0003 #plenary https://t.co/XdaaSFfxSP
David Liew drdavidliew
3 years 10 months ago
Question is: does early stage PNL protect vs vascular remodelling in GCA? What about TCZ?
Salvarini group:
18 new GCA pts
GUSTO Rx (TCZ +IVMPx3, no ongoing PNL)
PET/CT: 0, 24, 52w
inflamm controlled but aortic diltation
plausible concerns reinforced!
ABST0480 #ACR22 @RheumNow https://t.co/Wnw4oxaZn7
Janet Pope Janetbirdope
3 years 10 months ago
RECITAL trial #CTD with #ILD RCT of #rituximab vs #cyclophosphamide showed value overall with each Rx. Only 6 months as then maybe you would retreat w rituximab? Not superior on lungs but in #scleroderma-skin improvement better w RTX. #ACRBest #ACR22 @RheumNow abst#3 Impt for Rx https://t.co/lX1YPsr5U6
Mike Putman EBRheum
3 years 10 months ago
I implemented a Fast Track GCA clinic at my hospital (>60 encounters now!)
I have have begun to think the main benefit is ACCESS
Ultrasound is great and I do them, but I recommend starting one REGARDLESS of whether or not you do ultrasound
#ACR22 @RheumNow #0463 https://t.co/4uuotmNnoi
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 10 months ago
#ACR2022 Abstr#0003. Subgroup analysis from RECITAL RCT Rituximab vs Cyclophosphamide in CTD-ILD showed both therapies improved FVC in Myositis and MCTD but not Scleroderma. To interpret with caution (non-powered). Key message: To consider RTX as option for CTD-ILD @RheumNow https://t.co/NhJKXRdw7q
